Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics
- 126 Downloads
Purpose To measure peptide concentrations and mRNA expression of the IGF Family in breast cancer and to examine their associations with the disease features. Experimental design Fresh tumor samples were collected from 348 patients who underwent surgery for breast cancer. Tissue levels of mRNA and peptide of IGF-I, IGF-II, and IGFBP-3 were analyzed with real-time RT-PCR and ELISA, respectively. Cox proportional hazards regression model was used to examine the associations of IGF markers with patient survival. Results Age was inversely associated with IGF-I, IGF-II and IGFBP-3 at both mRNA and peptide levels. Small tumors, early TNM stages, or low grades were associated with high mRNA expression of IGFs and IGFBP-3. Hormone receptors were positively correlated with IGF-I and IGF-II expression. Survival analysis showed that patients with high expression of one of the IGF-I transcripts, IGF-IA, had lower risk of disease recurrence (HR = 0.47, 95%CI: 0.27–0.81) and death (HR = 0.35, 95%CI: 0.18–0.70) compared to those with low expression. High IGFBP-3 expression was also inversely associated with reduced risk of death (HR = 0.47, 95%CI: 0.23–0.95). Similar associations, however, were not observed when tissue levels of IGF-I peptide or IGFBP-3 protein were analyzed. High IGF-II peptide was related to increased risk of relapse (HR = 1.91, 95%CI: 1.12–3.27). Conclusion Our findings of high mRNA expression of IGFs and IGFBP-3 being associated with less aggressive tumors and favorable prognosis were consistent with previous observations, but were not supported by the measurement of tissue levels of IGF-I peptide and IGFBP-3 protein, suggesting that IGF mRNA expression and tissue levels of IGF peptides are regulated by different mechanisms and assessing these molecules in tumor tissue may have different implications.
KeywordsIGF-I IGF-II IGFBP-3 Prognosis
The study is supported in part by the AACR-Avon junior scholar-training award to Dr. Lina Mu. This study is also supported in part by the Regione Piemonte Grant to Dr. Dionyssios Katsaros and Dr. Irene. A. Rigault de la Longrais.
- 9.Dhar K, Banerjee S, Dhar G, Sengupta K, Banerjee SK (2007) Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells. Cancer Res 67:1520–1526PubMedCrossRefGoogle Scholar
- 10.Borowiec AS, Hague F, Harir N, Guenin S, Guerineau F, Gouilleux F, Roudbaraki M, Lassoued K, Ouadid-Ahidouch H (2007) IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation. J Cell Physiol 212:690–701PubMedCrossRefGoogle Scholar
- 17.Vadgama JV, Wu Y, Datta G, Khan H, Chillar R (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57:330–340PubMedCrossRefGoogle Scholar
- 22.Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D (1996) Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 88:601–606PubMedCrossRefGoogle Scholar
- 26.Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE (2005) Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. Breast Cancer Res 7:R119–R129PubMedCrossRefGoogle Scholar
- 30.Manni A, Wei L, Badger B, Zaenglein A, Leighton J, Shimasaki S, Ling N (1992) Expression of messenger RNA for insulin-like growth factors and insulin-like growth factor binding proteins by experimental breast cancer and normal breast tissue in vivo. Endocrinology 130:1744–1746PubMedCrossRefGoogle Scholar
- 31.Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, Taniya T, Noguchi M, Nakamura S, Matsubara F (1990) Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 10:1115–1126PubMedGoogle Scholar
- 37.Fichera E, Liang S, Xu Z, Guo N, Mineo R, Fujita-Yamaguchi Y (2000) A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. Growth Horm IGF Res 10:61–70PubMedCrossRefGoogle Scholar
- 43.Giani C, Campani D, Rasmussen A, Fierabracci P, Miccoli P, Bevilacqua G, Pinchera A, Cullen KJ (2002) Insulin-like growth factor II (IGF-II) immunohistochemistry in breast cancer: relationship with the most important morphological and biochemical prognostic parameters. Int J Biol Markers 17:90–95PubMedGoogle Scholar
- 46.Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CT Jr., Fontana JA (1994) Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 158:69–78PubMedCrossRefGoogle Scholar